COL4A3_HUMAN,R873K,0.027,-,-,-
COL4A3_HUMAN,D888G,0.318,-,-,-
COL4A3_HUMAN,A963T,0.043,-,-,-
COL4A3_HUMAN,P1008L,0.272,-,-,-
COL4A3_HUMAN,M1020R,0.415,-,-,-
COL4A3_HUMAN,P1132S,0.062,-,-,-
COL4A3_HUMAN,P1142I,0.637,Altered Disordered interface (Pr = 0.32 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000005|ELME000155|ELME000340,-
COL4A3_HUMAN,F1144D,0.388,-,-,-
COL4A3_HUMAN,R1241H,0.120,-,-,-
COL4A3_HUMAN,I1264T,0.079,-,-,-
COL4A3_HUMAN,K1279Q,0.186,-,-,-
COL4A3_HUMAN,V1344I,0.025,-,-,-
COL4A3_HUMAN,Q1480E,0.042,-,-,-
COL4A3_HUMAN,I1575V,0.050,-,-,-
COL4A3_HUMAN,F1586K,0.903,Altered Transmembrane protein (Pr = 0.36 | P = 1.5e-05); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Stability (Pr = 0.22 | P = 0.01), ELME000053|ELME000336,-
COL4A3_HUMAN,L1614I,0.048,-,-,-
COL4A3_HUMAN,N1627R,0.846,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 4.5e-04); Altered DNA binding (Pr = 0.27 | P = 6.1e-03); Altered Metal binding (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C1622 (Pr = 0.20 | P = 0.02), ELME000053|ELME000084|ELME000197,-
COL4A3_HUMAN,S1628K,0.829,Altered Transmembrane protein (Pr = 0.33 | P = 6.8e-05); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.26 | P = 7.3e-03); Altered Metal binding (Pr = 0.25 | P = 0.01); Gain of Acetylation at S1628 (Pr = 0.22 | P = 0.03), ELME000053|ELME000084|ELME000197|PS00005,-
COL4A3_HUMAN,S1630N,0.785,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.9e-04); Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.04); Altered DNA binding (Pr = 0.26 | P = 6.8e-03); Altered Metal binding (Pr = 0.24 | P = 0.02), ELME000053|ELME000197,-
COL4A3_HUMAN,W1632S,0.952,Altered Transmembrane protein (Pr = 0.33 | P = 4.9e-05); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered DNA binding (Pr = 0.30 | P = 2.6e-03); Gain of Helix (Pr = 0.29 | P = 0.01); Loss of Strand (Pr = 0.26 | P = 0.05); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered Stability (Pr = 0.15 | P = 0.02), ELME000063,-
COL4A3_HUMAN,N1637H,0.211,-,-,-
COL4A3_HUMAN,R1643K,0.249,-,-,-
COL4A3_HUMAN,K1644L,0.715,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of SUMOylation at K1644 (Pr = 0.21 | P = 0.03), ELME000102,-
COL4A3_HUMAN,E1656A,0.405,-,-,-
COL4A3_HUMAN,K1657F,0.426,-,-,-
COL4A3_HUMAN,I1658F,0.314,-,-,-
COL4A3_HUMAN,G1412V,0.933,Loss of B-factor (Pr = 0.34 | P = 1.7e-03); Loss of Methylation at K1408 (Pr = 0.28 | P = 1.1e-03); Gain of Acetylation at K1408 (Pr = 0.26 | P = 7.8e-03); Loss of SUMOylation at K1414 (Pr = 0.26 | P = 6.6e-03), ELME000064|PS00008,-
COL4A3_HUMAN,G532C,0.930,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K537 (Pr = 0.21 | P = 0.03); Loss of Methylation at K537 (Pr = 0.17 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q531 (Pr = 0.04 | P = 0.05), None,-
COL4A3_HUMAN,G265E,0.898,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Acetylation at K261 (Pr = 0.26 | P = 0.01); Loss of Methylation at K264 (Pr = 0.22 | P = 4.7e-03); Gain of SUMOylation at K264 (Pr = 0.22 | P = 0.02), None,-
COL4A3_HUMAN,G118R,0.923,Loss of Sulfation at Y117 (Pr = 0.01 | P = 0.05), ELME000120|ELME000155,-
COL4A3_HUMAN,G392E,0.795,Gain of Loop (Pr = 0.28 | P = 0.01); Altered Disordered interface (Pr = 0.23 | P = 0.03); Loss of Proteolytic cleavage at R391 (Pr = 0.14 | P = 0.02), ELME000005|ELME000155,-
COL4A3_HUMAN,G1192E,0.944,Gain of Loop (Pr = 0.30 | P = 6.5e-03); Loss of Acetylation at K1191 (Pr = 0.25 | P = 0.01); Loss of Methylation at K1191 (Pr = 0.25 | P = 2.4e-03); Loss of Ubiquitylation at K1191 (Pr = 0.17 | P = 0.03), None,-
COL4A3_HUMAN,G455C,0.909,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of Phosphorylation at Y456 (Pr = 0.26 | P = 0.03); Loss of Sulfation at Y456 (Pr = 0.01 | P = 0.05), None,-
COL4A3_HUMAN,G1155D,0.953,Loss of Methylation at R1154 (Pr = 0.13 | P = 0.02), PS00016,-
COL4A3_HUMAN,C1665Y,0.842,Altered Disordered interface (Pr = 0.50 | P = 4.6e-04); Loss of Intrinsic disorder (Pr = 0.38 | P = 0.03); Altered Metal binding (Pr = 0.33 | P = 0.01); Gain of Strand (Pr = 0.29 | P = 4.6e-03); Altered DNA binding (Pr = 0.23 | P = 9.8e-03), None,-
COL4A3_HUMAN,G1219C,0.934,Altered Disordered interface (Pr = 0.32 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Methylation at R1215 (Pr = 0.18 | P = 9.7e-03), ELME000064|ELME000220|PS00006,-
COL4A3_HUMAN,R1661C,0.803,Altered Metal binding (Pr = 0.58 | P = 3.1e-03); Altered Disordered interface (Pr = 0.36 | P = 9.2e-03); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), None,-
COL4A3_HUMAN,H495Y,0.183,-,-,-
COL4A3_HUMAN,G777D,0.961,Gain of Loop (Pr = 0.27 | P = 0.03), None,-
COL4A3_HUMAN,G836E,0.920,Gain of SUMOylation at K834 (Pr = 0.31 | P = 2.8e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K838 (Pr = 0.23 | P = 0.02); Loss of Methylation at K838 (Pr = 0.20 | P = 7.0e-03), ELME000048,-
COL4A3_HUMAN,G213R,0.938,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K215 (Pr = 0.19 | P = 0.05); Gain of SUMOylation at K215 (Pr = 0.19 | P = 0.04); Loss of Methylation at R212 (Pr = 0.18 | P = 9.0e-03), ELME000012|ELME000102|ELME000108|ELME000155,-
COL4A3_HUMAN,P1501Q,0.785,Altered Transmembrane protein (Pr = 0.28 | P = 4.0e-04); Loss of Disulfide linkage at C1505 (Pr = 0.21 | P = 0.02), ELME000048|ELME000062,-
COL4A3_HUMAN,G333A,0.908,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K332 (Pr = 0.25 | P = 0.01); Altered Metal binding (Pr = 0.19 | P = 0.04); Loss of Methylation at K329 (Pr = 0.17 | P = 0.01), None,-
COL4A3_HUMAN,F1475S,0.697,Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Altered Stability (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q1480 (Pr = 0.06 | P = 0.03), ELME000063|ELME000197|ELME000328,-
COL4A3_HUMAN,G1277S,0.904,Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Methylation at K1279 (Pr = 0.24 | P = 2.7e-03); Loss of SUMOylation at K1279 (Pr = 0.19 | P = 0.04), ELME000136|ELME000155|ELME000159|PS00005,-
COL4A3_HUMAN,G1080A,0.910,Loss of B-factor (Pr = 0.29 | P = 0.02); Loss of Acetylation at K1081 (Pr = 0.29 | P = 4.9e-03); Gain of SUMOylation at K1082 (Pr = 0.26 | P = 6.5e-03); Loss of Methylation at K1081 (Pr = 0.23 | P = 3.8e-03), ELME000093|PS00009,-
COL4A3_HUMAN,G631V,0.943,Gain of O-linked glycosylation at T629 (Pr = 0.19 | P = 0.02), ELME000052|ELME000155|ELME000202|ELME000336,-
COL4A3_HUMAN,G1164C,0.956,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K1169 (Pr = 0.27 | P = 7.5e-03); Loss of SUMOylation at K1169 (Pr = 0.26 | P = 6.2e-03); Loss of Methylation at K1169 (Pr = 0.20 | P = 7.0e-03); Loss of Ubiquitylation at K1169 (Pr = 0.16 | P = 0.03); Gain of Disulfide linkage at G1164 (Pr = 0.10 | P = 0.05), None,-
COL4A3_HUMAN,G91D,0.952,Gain of Acetylation at K90 (Pr = 0.23 | P = 0.02); Loss of Methylation at K90 (Pr = 0.20 | P = 6.8e-03); Gain of SUMOylation at K90 (Pr = 0.18 | P = 0.05); Gain of O-linked glycosylation at S96 (Pr = 0.11 | P = 0.05), ELME000336,-
COL4A3_HUMAN,G856E,0.839,Gain of Loop (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at T855 (Pr = 0.15 | P = 0.03), ELME000136|ELME000155|ELME000159,-
COL4A3_HUMAN,G43R,0.840,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K48 (Pr = 0.24 | P = 0.01); Loss of Acetylation at K45 (Pr = 0.23 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q38 (Pr = 0.19 | P = 2.5e-03); Loss of Methylation at K45 (Pr = 0.14 | P = 0.02), None,-
COL4A3_HUMAN,H451R,0.072,-,-,-
COL4A3_HUMAN,R408H,0.170,-,-,-
COL4A3_HUMAN,P116T,0.584,Gain of Sulfation at Y117 (Pr = 0.01 | P = 0.04), ELME000052,-
COL4A3_HUMAN,K834R,0.072,-,-,-
COL4A3_HUMAN,A24G,0.114,-,-,-
COL4A3_HUMAN,A26T,0.088,-,-,-
COL4A3_HUMAN,A26V,0.089,-,-,-
COL4A3_HUMAN,K51R,0.083,-,-,-
COL4A3_HUMAN,G73I,0.946,Loss of B-factor (Pr = 0.31 | P = 5.8e-03); Loss of Methylation at K78 (Pr = 0.21 | P = 5.3e-03); Gain of Acetylation at K78 (Pr = 0.20 | P = 0.04), ELME000155,-
COL4A3_HUMAN,S126N,0.067,-,-,-
COL4A3_HUMAN,Q132R,0.219,-,-,-
COL4A3_HUMAN,L141P,0.109,-,-,-
COL4A3_HUMAN,P144Q,0.171,-,-,-
COL4A3_HUMAN,P144R,0.332,-,-,-
COL4A3_HUMAN,E269Q,0.062,-,-,-
COL4A3_HUMAN,S310N,0.152,-,-,-
COL4A3_HUMAN,L322I,0.108,-,-,-
COL4A3_HUMAN,M323A,0.119,-,-,-
COL4A3_HUMAN,D355E,0.072,-,-,-
COL4A3_HUMAN,Q531E,0.123,-,-,-
COL4A3_HUMAN,L544H,0.413,-,-,-
COL4A3_HUMAN,V552A,0.038,-,-,-
COL4A3_HUMAN,K565N,0.380,-,-,-
COL4A3_HUMAN,V632A,0.100,-,-,-
COL4A3_HUMAN,P657L,0.157,-,-,-
COL4A3_HUMAN,P669L,0.134,-,-,-
COL4A3_HUMAN,I675M,0.043,-,-,-
COL4A3_HUMAN,M726L,0.070,-,-,-
COL4A3_HUMAN,P861S,0.244,-,-,-
COL4A3_HUMAN,P884L,0.094,-,-,-
COL4A3_HUMAN,Q926R,0.084,-,-,-
COL4A3_HUMAN,E946Q,0.073,-,-,-
COL4A3_HUMAN,D953H,0.208,-,-,-
COL4A3_HUMAN,L999F,0.124,-,-,-
COL4A3_HUMAN,T1002I,0.043,-,-,-
COL4A3_HUMAN,I1126T,0.125,-,-,-
COL4A3_HUMAN,D1156A,0.162,-,-,-
COL4A3_HUMAN,D1211E,0.138,-,-,-
COL4A3_HUMAN,T1238K,0.055,-,-,-
COL4A3_HUMAN,P1244R,0.388,-,-,-
COL4A3_HUMAN,S1246L,0.062,-,-,-
COL4A3_HUMAN,L1294R,0.522,Loss of Loop (Pr = 0.27 | P = 0.02); Gain of B-factor (Pr = 0.26 | P = 0.01); Gain of ADP-ribosylation at L1294 (Pr = 0.19 | P = 0.04); Gain of Methylation at L1294 (Pr = 0.16 | P = 0.01), ELME000005|ELME000093|ELME000097|ELME000102|ELME000108|ELME000155|PS00009,-
COL4A3_HUMAN,K1318T,0.178,-,-,-
COL4A3_HUMAN,I1330T,0.094,-,-,-
COL4A3_HUMAN,G1553A,0.307,-,-,-
COL4A3_HUMAN,T1587A,0.790,Altered Transmembrane protein (Pr = 0.29 | P = 2.5e-04); Altered Stability (Pr = 0.09 | P = 0.05), ELME000053|ELME000085|ELME000336,-
COL4A3_HUMAN,S1626I,0.781,Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered Disordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 4.1e-04); Gain of Strand (Pr = 0.28 | P = 0.01); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered DNA binding (Pr = 0.25 | P = 6.2e-03); Gain of Disulfide linkage at C1622 (Pr = 0.22 | P = 0.01), ELME000053|ELME000081|ELME000084|ELME000182,-
COL4A3_HUMAN,A1634S,0.497,-,-,-
